PATHWAY-BASED THERAPIES FOR AGE-RELATED MACULAR DEGENERATION: An Integrated Survey of Emerging Treatment Alternatives
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To review treatments under development for age-related macular degeneration (AMD) in the context of current knowledge of AMD pathogenesis. Methods: Review of the scientific literature published in English. Results: Steps in AMD pathogenesis that appear to be good targets for drug development include 1) oxidative damage; 2) lipofuscin accumulation; 3) chronic inflammation; 4) mutations in the complement pathway; and 5) noncomplement mutations that influence chronic inflammation and/or oxidative damage (e.g., mitochondria and extracellular matrix structure). Steps in neovascularization that can be targeted for drug development and combination therapy include 1) angiogenic factor production; 2) factor release; 3) binding of factors to extracellular receptors (and activation of intracellular signaling after receptor binding); 4) endothelial cell activation (and basement membrane degradation); 5) endothelial cell proliferation; 6) directed endothelial cell migration; 7) extracellular matrix remodeling; 8) tube formation; and 9) vascular stabilization. Conclusion: The era of pathway-based therapy for the early and late stages of AMD has begun. At each step in the pathway, a new treatment could be developed, but complete inhibition of disease progression will likely require a combination of the various treatments. Combination therapy will likely supplant monotherapy as the treatment of choice because the clinical benefits (visual acuity and frequency of treatment) will likely be superior to monotherapy in preventing the late-stage complications of AMD. The era of pathway-based therapy for the early and late stages of AMD has begun. At each step in the pathway, a new treatment could be developed, but complete inhibition of disease progression will likely require a combination of the various treatments. Combination therapy will likely supplant monotherapy as the treatment of choice because the clinical benefi ts (visual acuity and frequency of treatment) will likely be superior to monotherapy in preventing the late-stage complications of AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationComplement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
β-Carotene: an Unusual Type of Lipid Antioxidant
Burton, G. W., & Ingold, K. U. (1984) · Science · doi:10.1126/science.6710156 · Cited by 2,150 · cited 1×
“In low doses, beta-carotene can act as an antioxidant.(79) High doses of beta-carotene can reduce retinoic acid levels, possibly via stimulation of cytochrome P450 activity because of the formation of eccentric cleavage products (vs.”
BackgroundHageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
Hageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265 · cited 1×
“Anatomical studies demonstrate the presence of inflammatory cells in Bruch membrane.(30) Bioactive fragments of C3 (C3a) and C5 (C5a) are present in the drusen of AMD eyes and induce vascular endothelial growth factor (VEGF) expression in RPE cells.”
BackgroundDrusen proteome analysis: an approach to the etiology of age-related macular degeneration
Crabb, J. W., Miyagi, M., Gu, X., Shadrach, K., West, K. A., Sakaguchi, H., Kamei, M., Hasan, A., Yan, L., Rayborn, M. E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222551899 · Cited by 1,208 · cited 2×
“Advanced glycation end products occur in soft drusen, basal laminar and basal linear deposits, and the cytoplasm of RPE cells associated with choroidal neovascularization (CNV).(5,6) Carboxymethyl lysine is present in drusen and CNV(5,7) as are carboxyethyl pyrrole protein adducts.”
Background
Cited by
Mullins, R. F., Johnson, M. N., Faidley, E. A., Skeie, J. M., & Huang, J. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6476 · Cited by 394
OCT angiography and evaluation of the choroid and choroidal vascular disorders
Borrelli, E., Sarraf, D., Freund, K. B., & Sadda, S. R. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.07.002 · Cited by 321
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
Zhang, K., Zhang, L., & Weinreb, R. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3745 · Cited by 316
Yehoshua, Z., Alexandre de Amorim Garcia Filho, C., Nunes, R. P., Gregori, G., Penha, F. M., Moshfeghi, A. A., Zhang, K., Sadda, S., Feuer, W., & Rosenfeld, P. J. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.044 · Cited by 299
Self-citationEvaluation of Age-related Macular Degeneration With Optical Coherence Tomography
Keane, P. A., Patel, P. J., Liakopoulos, S., Heussen, F. M., Sadda, S. R., & Tufail, A. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.006 · Cited by 280
Metadata
- Authors
- Zarbin, M. A., & Rosenfeld, P. J.
- Venue
- Retina
- Published
- 2010-10
- Volume
- 30
- Issue
- 9
- Pages
- 1350-1367
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2028350502
- Cited by
- 140
- References
- 41
- FWCI
- 19.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PATHWAY-BASED THERAPIES FOR AGE-RELATED MACULAR DEGENERATION: An Integrated Survey of Emerging Treatment Alternatives. https://app.cochat.ai/papers/10.1097/iae.0b013e3181f57e30
- The paper
- Zarbin, M. A., & Rosenfeld, P. J. (2010). PATHWAY-BASED THERAPIES FOR AGE-RELATED MACULAR DEGENERATION: An Integrated Survey of Emerging Treatment Alternatives. Retina. https://doi.org/10.1097/iae.0b013e3181f57e30
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.